
Amol Mehta, MD
@amolmehtamd
Neuroendovascular Surgery Fellow @MountSinai former @Columbianeuron Interested in: Neurointervention, Stroke, Public Health, Jazz Saxophone
ID: 803458464
04-09-2012 23:56:19
214 Tweet
304 Takipçi
346 Takip Edilen


Thank you to JNIS for publishing our study on EVT for patients with existing disability! Daryl Goldman MD Shahram Majidi, MD Mount Sinai Cerebrovascular Mount Sinai Neurosurgery





Mt. Sinai Neuroendovascular fellows 2025-2026: Amol Mehta Trevor Hardigan Joseph Yoon Jennifer Watchmaker Mount Sinai Neurosurgery SNIS Info SVIN CV Section


At #SNIS2025! 🚨 Amol Mehta, MD, #Neuroendovascular surgery fellow at Mount Sinai Cerebrovascular & Mount Sinai Neurosurgery, presents “Beyond the First Pass Effect!" His talk explores how inter-pass time impacts #Stroke procedure success. Research mentored by Shahram Majidi, MD. SNIS Info #Neurosurgery


Dr. Amol Mehta presenting on inter pass time to procedural efficacy and clinical outcome. Interpass time of less than 8 minutes improves 90 day outcomes! #SNIS2025 @SNISInfo ESMINT Society CV Section Felipe C. Albuquerque Michael Chen, MD Dr. DiestroKE Matthew Amans Andrew Ducruet Matt Fusco


How do you assess liquid embolic penetration in MMA embolization? Dr. Daryl Goldman shows the SLEEK grading system shows deeper penetration leads to faster cSDH resolution. #snis2025 @SNISInfo ESMINT Society CV Section Felipe C. Albuquerque Michael Chen, MD Dr. DiestroKE Matthew Amans


So proud to see Dr Fifi Johanna T. Fifi, MD deliver the SNIS president’s address! Mount Sinai Neurosurgery Mount Sinai Cerebrovascular #SNIS #standingovation





Being a senior fellow is sweett. TICI3 1 pass, 7 min groin puncture to recanalization! With Zoom 7X and CDAT! Imperative Care Vascular under the auspices of Shahram Majidi, MD NIHSS 7->1 and no infarct on MRI

Thrilled to publish this piece in Stroke AHA/ASA alongside several of my mentors to hopefully clarify current dilemmas on the treatment of M2 occlusions, and to encourage the community to treat proximal/dominant M2s in the post MEVO trial era.
